Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece
A phase 3 trial of Cabozantinib, Sorafenib, Atezolizumab in hepatocellular carcinoma, run by Exelixis, active and no longer recruiting.
Overview
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy is a phase 3 interventional study registered as NCT03755791 by Exelixis, with 837 participants enrolled, started 2018-06-10 and due to reach its primary completion in 2021-11-30. Interventions recorded: Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va
Shares Exelixis, Cabozantinib.
- TrialStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Shares Exelixis, Cabozantinib, Atezolizumab.
- TrialCELESTIAL
Shares Cabozantinib, Hepatocellular carcinoma.
- TrialSARAH and SIRveNIB
Shares Sorafenib, Hepatocellular carcinoma.
- TrialStudy of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Shares Exelixis, Atezolizumab.
- TrialSHARP
Shares Sorafenib, Hepatocellular carcinoma.
- TargetAXL
Shares Cabozantinib, Hepatocellular carcinoma.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Hepatocellular carcinoma.